Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treatment with remibrutinib
A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by extended treatment with open-label remibrutinib
What was tested
Treatment tested
- Remibrutinib
Compared with
- Teriflunomide
Dihydroorotate dehydrogenase inhibitor
What it measured
Main measures
Core part:
Other measures (1)
Core part:
Papers
Loading reviews and guidelines…
Related trials
- REDIFINE MS
Recruiting
Still running
- FENerations1
Phase 2 · Recruiting
Still running
- CLOU064C12306
Phase 3 · Recruiting
Still running
- A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Pl…
Phase 2 · Withdrawn
Stopped early
- FENopta
Phase 2 · Running, not recruiting
Met its main goal
- A Study of Orelabrutinib in Patients With Relapsing-Remit…
Phase 2 · Completed
History
- In scope changed from true to false
Started
Nov 2021
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error